Clinical Trials Market to Approach $69.9 Billion by 2027

21/dic/2020 07:17:57 Grand View Research Contatta l'autore

Questo comunicato è stato pubblicato più di 30 giorni fa. Le informazioni su questa pagina potrebbero non essere attendibili.

The global clinical trials market size is expected to reach USD 69.9 billion by 2027, according to a new report by Grand View Research, Inc. It is projected to exhibit a CAGR of 5.1% during the forecast period. An increase in the volume and complexity of clinical trials has been witnessed lately, which plays an important role in the R&D of new drugs and other products. Also, clinical trials have become increasingly costly ventures, adding to the overall cost of developing a drug. Hence, big pharmaceuticals as well as small biotechnology firms are looking for innovative ways to improve trial outcomes and decrease trial costs.

The increasing need to develop new therapeutics for chronic diseases such as cancer, respiratory disorder, diabetes, cardiovascular disease, and others is creating immense pressure on healthcare. The global pandemic caused due to COVID-19 (coronavirus) and the increasing demand for developing a suitable treatment for the same is driving the market growth. The number of people affected by the coronavirus has reached one million, which further depicts an increasing need for therapeutics and vaccines. Currently, there are 288 therapeutics and 106 vaccines in development. Out of this, nearly 7.0% therapeutics are in Phase IV, 21.0% in Phase III, 43.0% & 13.0% in Phase II & Phase I respectively.

The pandemic has also resulted in global disruption of traditional onsite clinical trials. Hence, the regulatory bodies all over the world have launched various initiatives for fast-tracking clinical trials for the development of innovative solutions. One such instance is Solidarity, an international clinical trial launched by the World Health Organization (WHO) to find effective treatment against COVID-19.

Though COVID-19 is forcing many medical device & drug developers to revise the approach they prepare for these types of crises, integrating best practices within clinical trial procedures and adapting to virtual trials can support the continuous development of therapeutics even in the presence of this pandemic.

Clinical Trials Market Report Highlights

·         Phase III clinical trials dominated the market with a revenue share of 53.0% in 2019. This is attributed to the complexity level associated with this phase

·         The interventional design segment accounted for the largest market share of 45.6% in 2019 in the study design segment owing to the increasing demand for the intervention for clinical trials by researchers

·         North America held 51.2% of the market share in 2019. Favorable government initiatives and the presence of large numbers of players in U.S. offerings advanced services are responsible for the growth

·         Asia Pacific is expected to expand at the fastest CAGR of 6.1% over the forecast period owing to the increasing patient pool and cost-efficient services

Browse Details of Report @

Clinical Trials Market Segmentation

Grand View Research has segmented the global clinical trials market based on phase, study design, indication, and region:

Clinical Trials Phase Outlook (Revenue, USD Million, 2016 - 2027)

·         Phase I

·         Phase II

·         Phase III

·         Phase IV

Clinical Trials Study Design Outlook (Revenue, USD Million, 2016 - 2027)

·         Interventional

·         Observational

·         Expanded Access

Clinical Trials Indication Outlook (Revenue, USD Million, 2016 - 2027)

·         Autoimmune/Inflammation

·         Pain management

·         Oncology

·         CNS condition

·         Diabetes

·         Obesity

·         Cardiovascular

·         Others

blog comments powered by Disqus è un servizio offerto da Factotum Srl